Visipaque: a contrast medium option when considering the special needs of more vulnerable patients.*
With more than 30 years of experience in providing diagnostic imaging solutions, GE Healthcare offers iodinated contrast media with a choice of osmolality that may help meet the individual needs of your patients.
Every patient case presents a unique clinical scenario. As with any procedure, it is important that the contrast media selection be based on each patient’s medical history, present condition, comorbidities and reasons for diagnostic assessment.
Proven to help manage risk in vulnerable patient populations
Approved for use in a broad range of intra-arterial and intravenous indications, Visipaque provides numerous benefits over low-osmolar contrast media (LOCM) agents in vulnerable patient populations,2-7 which include the following:*
- Managing renal risk in patients vulnerable to contrast-induced acute kidney injury2,3
- Minimising major adverse cardiac events (MACE)4,5
- Managing pain or discomfort on injection, particularly in those patients undergoing peripheral angiography procedures6
Visipaque is formulated with balanced electrolytes
- Visipaque is enriched with sodium and calcium in a physiologically favourable ratio to help minimise arrhythmias8,9,10
A range of concentrations and convenient sizes**
- 270 mgI/mL and 320 mgI/mL7
- 20, 50, 100, 200 and 500 mL7
**Concentrations, volumes and packaging vary from country to country
1. Davidson C, Laskey W, Hermiller J et al. Am J Cardiol 2006; 98 (Suppl. 1): 42k-58k.
2. McCullough P. Cardiorenal Med 2011; 1: 220-34.
3. Dong M, Jiao Z, Liu T et al. J Nephrol 2012; 25(3): 290-301.
4. Davidson CJ, Laskey WK, Hermiller JB et al. Circulation 2000; 101: 2172-7.
5. Harrison JK. Am Heart J 2004; 147: 613-14.
6. Rosenberg C et al. J Invasive Cardiol. 2017; 29(1):9-15
7. Visipaque Summary of Product Characteristics UK, April 2015.
8. Almen T. Acta Radiol 1995; 36 (Suppl. 399): 2-18.
9. Fountaine H et al. Acad Radiol 1996; 3 (Suppl.3): S475-84.
10. Jynge P. Eur Radiol 1996; 6 (Suppl.2): S8-S12.